DEPRE'5研究:SSRI治疗失败后重性抑郁五种二线策略比较
DEPRE'5为实用型多中心五臂平行组随机对照试验,纳入257例SSRI疗效不足的重性抑郁患者,比较SSRI剂量优化与四种二线策略。第6周盲法评估显示,替代策略组应答率高于剂量优化组(28.2%对14.3%,OR=2.36,p=0.05),文拉法辛转换和联合问题解决疗法结果最一致,但统计效能有限。
要点
- SSRI疗效不足时,换用文拉法辛或联合问题解决疗法结果最一致。
- 替代二线策略总体应答率优于SSRI剂量优化,但缓解率差异无统计学意义。
- SSRI联合问题解决疗法不良反应最少,SSRI联合去甲替林最多。
核心结论
- 对SSRI应答不足的重性抑郁患者,除剂量优化外的任何二线策略可能带来获益。
- 在统计效能有限的情况下,换用文拉法辛和联合心理治疗在DEPRE'5研究中结果最一致。
研究设计与样本
- 实用型、多中心、五臂平行组随机对照试验,采用盲法评估。
- 共257例SSRI疗效不足的重性抑郁患者随机分配:SSRI剂量优化51例、SSRI联合锂盐46例、SSRI联合去甲替林48例、换用文拉法辛55例、SSRI联合问题解决疗法57例。
主要发现
- 第6周应答率:替代二线策略组28.2%对SSRI剂量优化组14.3%,OR=2.36(95%CI 1.0-5.6),p=0.05。
- 第6周缓解率:替代二线策略组16.9%对SSRI剂量优化组12.2%,OR=1.46(95%CI 0.57-3.71),p=0.27。
- HDRS-17评分下降:替代二线策略组较SSRI剂量优化组多降2.6分(95%CI -4.9至-0.4),p=0.021。
- 换用文拉法辛组应答OR=2.53(95%CI 0.94-6.80),p=0.067;HDRS-17差值-2.7(95%CI -5.5至0.0),p=0.054。
- SSRI联合问题解决疗法组应答OR=2.46(95%CI 0.92-6.62),p=0.074;HDRS-17差值-3.1(95%CI -5.8至-0.3),p=0.032。
关键数值与推荐
- 主要结局为第6周应答率和缓解率,采用盲法评估的17项汉密尔顿抑郁量表(HDRS-17)评定。
- 不良反应:SSRI联合问题解决疗法组报告最少,SSRI联合去甲替林组最多(28.1%对75%,p<0.01),大多为轻度。
临床怎么用
- SSRI疗效不足时,可考虑换用文拉法辛或联合问题解决疗法,而非仅做剂量优化。
- 选择二线策略时需权衡不良反应,SSRI联合去甲替林不良反应较多。
局限性
- 研究统计效能有限,部分比较未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major depressive disorder (MDD), but initial outcomes can be modest. AIMS: To compare SSRI dose optimisation with four alternative second-line strategies in MDD patients unresponsive to an SSRI. METHOD: Of 257 participants, 51 were randomised to SSRI dose optimisation (SSRI-Opt), 46 to lithium augmentation (SSRI+Li), 48 to nortriptyline combination (SSRI+NTP), 55 to switch to venlafaxine (VEN) and 57 to problem-solving therapy (SSRI+PST). Primary outcomes were week-6 response/remission rates, assessed by blinded evaluators using the 17-item Hamilton Depression Rating Scale (HDRS-17). Changes in HDRS-17 scores, global improvement and safety outcomes were also explored. EudraCT No. 2007-002130-11. RESULTS: Alternative second-line strategies led to higher response (28.2% v. 14.3%, odds ratio = 2.36 [95% CI 1.0-5.6], p = 0.05) and remission (16.9% v. 12.2%, odds ratio = 1.46, [95% CI 0.57-3.71], p = 0.27) rates, with greater HDRS-17 score reductions (-2.6 [95% CI -4.9 to -0.4], p = 0.021]) than SSRI-Opt. Significant/marginally significant effects were only observed in both response rates and HDRS-17 decreases for VEN (odds ratio = 2.53 [95% CI 0.94-6.80], p = 0.067; HDRS-17 difference: -2.7 [95% CI -5.5 to 0.0], p = 0.054) and for SSRI+PST (odds ratio = 2.46 [95% CI 0.92 to 6.62], p = 0.074; HDRS-17 difference: -3.1 [95% CI -5.8 to -0.3], p = 0.032). The SSRI+PST group reported the fewest adverse effects, while SSRI+NTP experienced the most (28.1% v. 75%; p < 0.01), largely mild. CONCLUSIONS: Patients with MDD and insufficient response to SSRIs would benefit from any other second-line strategy aside from dose optimisation. With limited statistical power, switching to venlafaxine and adding psychotherapy yielded the most consistent results in the DEPRE'5 study.
引用
- Pérez V, Puigdemont D, de Diego-Adeliño J, et al. The DEPRE'5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment. Br J Psychiatry. 2025. PMID: 40530754. doi:10.1192/bjp.2025.13
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。